StockNews.AI
DCGO
StockNews.AI
173 days

DocGo Announces Fourth Quarter and Full-Year 2024 Results

1. DocGo's 2024 revenue decreased to $616.6 million from $624.2 million in 2023. 2. GAAP gross margin improved to 32.1% in 2024 from 28.7% in 2023.

Earnings
-21.17%Current Return
VS
+1.55%S&P 500
$3.9202/27 04:49 PM EDTEvent Start
$3.0902/28 11:10 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bearish?

The decrease in revenue signals potential challenges in growth. Historically, revenue declines can negatively influence investor sentiment and stock prices, as seen with similar firms facing similar situations.

How important is it?

The article highlights significant financial results that directly relate to DCGO's performance, impacting investor trust and future earnings.

Why Short Term?

Immediate reactions to the revenue decline will likely impact stock prices in the near term. Recent examples include companies experiencing swift sell-offs after reporting lower-than-expected revenues.

Related Companies

CLOVAMEDHCA
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter and full-year ended December 31, 2024. Full-Year 2024 Financial Highlights Full-year 2024 revenue was $616.6 million, compared to $624.2 million for the full-year 2023. GAAP gross margin (which includes non-cash depreciation expenses) for the full-year 2024 was 32.1%, compared to 28.7% fo.

Related News